Gemfibrozil — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hyperlipidemia

• Atorvastatin
• Ezetimibe
• Fenofibrate
• Lovastatin
• Pravastatin
• Rosuvastatin
• Simvastatin

Other medications in Heart & Cardiovascular

• Hydralazine
• Hydrochlorothiazide
• Icosapentaenoic Acid
• Iloprost
• Inclisiran
• Indapamide
• Irbesartan
• Isosorbide Dinitrate

About Gemfibrozil

Gemfibrozil is a trusted medication often prescribed to manage dangerously high triglyceride levels, a key factor in cardiovascular health. At TheDrugClub, we believe essential medications like gemfibrozil should be accessible and affordable. Our members can enjoy significant savings, often receiving their gemfibrozil prescription with a $0 co-pay and the added convenience of free home delivery.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Gemfibrozil is approved for (FDA label)

Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis.

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Gemfibrozil (FDA label)

In the double-blind controlled phase of the primary prevention component of the Helsinki Heart Study, 2046 patients received gemfibrozil for up to five years. In that study, the following adverse reactions were statistically more frequent in subjects in the gemfibrozil group: Gallbladder surgery was performed in 0.9% of gemfibrozil and 0.5% of placebo subjects in the primary prevention component, a 64% excess, which is not statistically different from the excess of gallbladder surgery observed in the clofibrate group compared to the placebo group of the WHO study. Gallbladder surgery was also performed more frequently in the gemfibrozil group compared to the placebo group (1.9% versus 0.3%, p=0.07) in the secondary prevention component.

Source: FDA prescribing information (DailyMed). Set ID: 42e40524-57e9-4fee-993f-be0fda14936b. SPL document ID: 5a995e23-7803-cd31-e063-6294a90a7f56. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Gemfibrozil (FDA label)

1. Hepatic or severe renal dysfunction, including primary biliary cirrhosis. 2. Preexisting gallbladder disease (see WARNINGS ). 3. Hypersensitivity to gemfibrozil. 4. Combination therapy of gemfibrozil with simvastatin (see WARNINGS and PRECAUTIONS ). 5. Combination therapy of gemfibrozil with repaglinide (see PRECAUTIONS ). 6. Combination therapy of gemfibrozil with dasabuvir (see PRECAUTIONS ). 7. Combination therapy of gemfibrozil with selexipag (see PRECAUTIONS ).

Source: FDA prescribing information (DailyMed). Set ID: 42e40524-57e9-4fee-993f-be0fda14936b. SPL document ID: 5a995e23-7803-cd31-e063-6294a90a7f56. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.